Sometimes drugs have a surprising use.
Generalized Anxiety Disorder (GAD) stands out with persistent and excessive worry, disrupting daily tasks and personal connections. Treatments include psychotherapy, medication, and lifestyle adjustments, offering manageable paths for those affected.
Mind Medicine (MindMed) Inc., known for pioneering brain health treatments, shared promising Phase 2b trial results involving MM-120 (lysergide d-tartrate) for GAD. Dr. Daniel Karlin, MindMed’s chief medical officer, highlighted findings from a study involving 198 GAD patients across 20 US clinical sites.
Participants received a single dose of MM-120 or a placebo, divided into various dosage groups. Notably, no additional therapy was provided, assessing the drug’s standalone impact. Four weeks post-dosing, patients receiving 100 or 200 µg doses showed a significant response, with 78% displaying improvement and 50% achieving clinical remission.
Dr. Heather Tarbet, Amani Ag’s VP of research & development, emphasized the study’s implications in improving psychedelic therapy’s tolerability and accessibility. Modifying LSD to reduce its effects while preserving therapeutic benefits could address safety concerns, making such therapies more widely accepted among diverse patient groups.
Dr. Walker Porterfield from Clarity Hyperbarics advised caution, citing the trial’s small sample size and short duration. Notably, placebo group patients also showed improvement, raising questions about genuine effectiveness. He suggested further studies for conclusive assessments.
Dr. Karlin mentioned ongoing evaluation up to 12 weeks post-dosing, with data expected in early 2024. The complete study results will be presented at a scientific conference next year, followed by an FDA meeting and potential Phase 3 trials in the latter half of 2024, pending meeting outcomes.
Discussion about this post